IL2 and chronic graft versus host disease: After the assessment period, four patients developed chronic GVHD at day+31 (severe), day+72 (moderate), day+192 (mild), and day+346 (moderate) post IL-2 NK cell infusion, corresponding to days 142, 155, 267, and 446 after allo-HSCT, respectively (Table 2).